GATA3 germline variant is associated with CRLF2 expression and predicts outcome in pediatric B‐cell precursor acute lymphoblastic leukemia

The germline variant at rs3824662 in GATA3 is a risk locus for Philadelphia‐like acute lymphoblastic leukemia (Ph‐like ALL), the biological subtype of B‐cell precursor (BCP)‐ALL defined by a distinct gene expression profile and the presence of specific somatic aberrations including rearrangements of CRLF2. In this study, we investigated whether rs3824662 in GATA3 associates with CRLF2 expression in leukemic cells and predicts prognosis in pediatric BCP‐ALL patients treated according to the ALL Intercontinental Berlin‐Frankfurt‐Münster (IC BFM) 2009 (n = 645) and the ALL IC BFM 2002 (n = 216) protocols. High expression of CRLF2 was observed at both protein and mRNA levels (fourfold higher in AA than in CA + CC) among GATA3 AA variant carriers, independent of the presence of P2RY8‐CRLF2 fusion. Additionally, the AA variant at rs3824662 was a significant factor affecting minimal residual disease level at the end of induction phase and overall survival regardless of the risk group and the protocol. The germline variant at rs3824662 in GATA3 is a prognostic factor which associates with CRLF2 expression in leukemic cells supporting the hypothesis that GATA3 may have a regulatory effect on the CRLF2 pathway in pediatric BCP‐ALL.

[1]  M. Lejman,et al.  Surface expression of Cytokine Receptor-Like Factor 2 increases risk of relapse in pediatric acute lymphoblastic leukemia patients harboring IKZF1 deletions , 2018, Oncotarget.

[2]  M. Loh,et al.  Characterization of Causal Variants at the GATA3 Loci Associated with Susceptibility to Ph-like Acute Lymphoblastic Leukemia , 2017 .

[3]  Lara E Sucheston-Campbell,et al.  Genetic association with B-cell acute lymphoblastic leukemia in allogeneic transplant patients differs by age and sex. , 2017, Blood advances.

[4]  M. Lejman,et al.  Biallelic loss of CDKN2A is associated with poor response to treatment in pediatric acute lymphoblastic leukemia , 2017, Leukemia & lymphoma.

[5]  Y. Mosaad,et al.  GATA3 rs3824662 gene polymorphism as possible risk factor in a cohort of Egyptian patients with pediatric acute lymphoblastic leukemia and its prognostic impact , 2017, Leukemia & lymphoma.

[6]  P. Campbell,et al.  Characterisation of the genomic landscape of CRLF2‐rearranged acute lymphoblastic leukemia , 2017, Genes, chromosomes & cancer.

[7]  M. D. Den Boer,et al.  Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia. , 2016, Blood.

[8]  A. Moorman.  New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia , 2016, Haematologica.

[9]  M. Relling,et al.  Inherited genetic variation in childhood acute lymphoblastic leukemia. , 2015, Blood.

[10]  R. Fulton,et al.  Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children , 2015, Nature Communications.

[11]  C. Mullighan,et al.  Genomics in acute lymphoblastic leukaemia: insights and treatment implications , 2015, Nature Reviews Clinical Oncology.

[12]  M. Loh,et al.  A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. , 2014, Blood.

[13]  L. Gautier,et al.  Genomic profiling of thousands of candidate polymorphisms predicts risk of relapse in 778 Danish and German childhood acute lymphoblastic leukemia patients , 2014, Leukemia.

[14]  C. Mullighan.  The genomic landscape of acute lymphoblastic leukemia in children and young adults. , 2014, Hematology. American Society of Hematology. Education Program.

[15]  J. Downing,et al.  Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Heather L. Mulder,et al.  Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. , 2014, The New England journal of medicine.

[17]  D. J. Moulton,et al.  Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment , 2014, Leukemia.

[18]  I. Smirnov,et al.  Genomic ancestry and somatic alterations correlate with age at diagnosis in Hispanic children with B‐cell acute lymphoblastic leukemia , 2014, American journal of hematology.

[19]  Y. Wan.  GATA3: a master of many trades in immune regulation. , 2014, Trends in immunology.

[20]  O. Hrusak,et al.  Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Thomas W. Mühleisen,et al.  Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype. , 2013, Blood.

[22]  A. Chokkalingam,et al.  GATA3 risk alleles are associated with ancestral components in Hispanic children with ALL. , 2013, Blood.

[23]  M. Loh,et al.  Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse , 2013, Nature Genetics.

[24]  F. Uckun,et al.  Absence of Genomic Ikaros/IKZF1 Deletions in Pediatric B-Precursor Acute Lymphoblastic Leukemia. , 2013, International journal of molecular medical science.

[25]  Cheng Cheng,et al.  Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. , 2012, Blood.

[26]  M. Schrappe,et al.  Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia , 2012, Leukemia.

[27]  C. Mullighan.  Molecular genetics of B-precursor acute lymphoblastic leukemia. , 2012, The Journal of clinical investigation.

[28]  O. Haas,et al.  Treatment outcome of CRLF2 ‐rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP‐BFM and UK NCRI‐CCLG study groups , 2012, British journal of haematology.

[29]  H. Kestler,et al.  Early relapse in ALL is identified by time to leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways. , 2011, Cancer cell.

[30]  M. Loh,et al.  Understanding the biology of CRLF2-overexpressing acute lymphoblastic leukemia. , 2011, Critical reviews in oncogenesis.

[31]  M. Relling,et al.  ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence , 2010, Leukemia.

[32]  J. Downing,et al.  Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia , 2009, Nature Genetics.

[33]  Ching-Hon Pui,et al.  Germline genomic variants associated with childhood acute lymphoblastic leukemia , 2009, Nature Genetics.

[34]  Cheng Cheng,et al.  Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. , 2009, JAMA.

[35]  Christopher B. Miller,et al.  BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros , 2008, Nature.

[36]  Christopher B. Miller,et al.  Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.

[37]  B. Morris,et al.  The Human Pseudoautosomal Region (PAR): Origin, Function and Future. , 2007, Current Genomics.

[38]  P. Gaynon.  Childhood acute lymphoblastic leukaemia and relapse , 2005, British journal of haematology.

[39]  S. Galimberti,et al.  Outcome of very late relapse in children with acute lymphoblastic leukemia. , 2004, Haematologica.

[40]  M. Schrappe,et al.  Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study. , 2000, Blood.